Accommodating IOL's new design shows benefits

Results of a multicenter FDA clinical trial of a fourth-generation version of an accommodating IOL (crystalens HD-100, eyeonics/Bausch & Lomb) demonstrate that the lens provides excellent uncorrected visual acuity at all distances that exceeds those of previous versions and without causing loss of contrast sensitivity.

Related Videos
Related Content
© 2023 MJH Life Sciences

All rights reserved.